argenex’s (ARGX) Hold (C) Rating Reiterated at Weiss Ratings

Weiss Ratings reiterated their hold (c) rating on shares of argenex (NASDAQ:ARGX) in a research note published on Friday morning,Weiss Ratings reports.

Several other equities research analysts also recently weighed in on ARGX. Deutsche Bank Aktiengesellschaft downgraded argenex from a “buy” rating to a “hold” rating in a report on Thursday, September 11th. Morgan Stanley upped their price target on argenex from $766.00 to $1,040.00 and gave the stock an “overweight” rating in a report on Wednesday, October 1st. Truist Financial upped their price target on argenex from $700.00 to $918.00 and gave the stock a “buy” rating in a report on Monday, September 15th. Wells Fargo & Company upped their price target on argenex from $741.00 to $756.00 and gave the stock an “overweight” rating in a report on Thursday, July 31st. Finally, Royal Bank Of Canada started coverage on argenex in a report on Monday, August 25th. They set an “outperform” rating and a $850.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, argenex presently has an average rating of “Moderate Buy” and an average target price of $817.53.

argenex Trading Up 0.6%

ARGX stock opened at $817.32 on Friday. The company has a market capitalization of $50.32 billion, a PE ratio of 41.91, a P/E/G ratio of 0.89 and a beta of 0.46. argenex has a 12-month low of $510.05 and a 12-month high of $855.46. The business’s fifty day moving average price is $752.66 and its 200 day moving average price is $645.81.

argenex (NASDAQ:ARGX) last posted its quarterly earnings data on Thursday, July 31st. The company reported $3.74 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.84 by $0.90. The firm had revenue of $866.79 million for the quarter, compared to the consensus estimate of $776.82 million. argenex had a return on equity of 21.06% and a net margin of 40.98%. Research analysts predict that argenex will post 3.13 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in ARGX. Janney Montgomery Scott LLC boosted its position in shares of argenex by 41.6% during the 1st quarter. Janney Montgomery Scott LLC now owns 1,141 shares of the company’s stock worth $675,000 after acquiring an additional 335 shares in the last quarter. Cambridge Investment Research Advisors Inc. acquired a new position in shares of argenex during the 1st quarter worth about $583,000. Oppenheimer & Co. Inc. boosted its position in shares of argenex by 10.2% in the 1st quarter. Oppenheimer & Co. Inc. now owns 915 shares of the company’s stock valued at $542,000 after purchasing an additional 85 shares during the period. Golden State Wealth Management LLC acquired a new stake in shares of argenex in the 1st quarter valued at about $44,000. Finally, Sequoia Financial Advisors LLC boosted its position in shares of argenex by 1.3% in the 1st quarter. Sequoia Financial Advisors LLC now owns 1,829 shares of the company’s stock valued at $1,083,000 after purchasing an additional 24 shares during the period. 60.32% of the stock is owned by institutional investors and hedge funds.

argenex Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.